ADMA BIOLOGICS, INC. (ADMA) Return on equity 2017–2025
ADMA BIOLOGICS, INC. (ADMA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
30.8%FY2025 · since FY2017: -108.5% → 30.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 30.8% | -25.9 pp |
| FY2024 | 56.6% | +77.5 pp |
| FY2023 | -20.9% | +22.5 pp |
| FY2022 | -43.4% | +7.4 pp |
| FY2021 | -50.8% | +35.1 pp |
| FY2020 | -85.8% | +98.5 pp |
| FY2019 | -184.3% | +148.2 pp |
| FY2018 | -332.5% | -224.0 pp |
| FY2017 | -108.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ADMA financial trends
ADMA RevenueADMA Net incomeADMA Net marginADMA Gross profitADMA Gross marginADMA Operating incomeADMA Operating marginADMA Operating cash flowADMA Free cash flowADMA Capital expendituresADMA Stock buybacksADMA Dividends paidADMA Total assetsADMA Total liabilitiesADMA Shareholders’ equityADMA overview →